AN OVERVIEW ON NON STEROIDAL ANTI-INFLAMMATORY DRUG AS A TRIGGER OF CARDIOVASCULAR DISEASE.
- Department of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Komarapalayam-638183, Tamil Nadu, India (Affiliated to the Tamilnadu Dr. MGR Medical University, Chennai, India).
8 Downloads
163 Views
Abstract
Nonsteroidal anti inflammatory drugs which are widely used by elderly patients. It have undesirable side effect including ulcers, bleeding, kidney failure and raised risk of heart and stroke. Mechanism of action, prolonged exposure to any class of non steroidal anti inflammatory drugs has been shown to have potential adverse effects on cardiovascular events in patients with or without pre existing cardiovascular conditions, depending on the duration and dosage of these drugs. Patient which having pre-existing coronary artery disease, hypertension, and history of stroke are at the higher risk of cardiovascular disease after taking non steroidal anti inflammatory drugs. The use of non steroidal anti inflammatory drugs with other antiplatelet drugs (except aspirin) increased the rate of cardiovascular events.Cyclooxygenase-2 inhibition results in a reduction of prostaglandin synthesis and is associated with both anti natriuretic and vasoconstrictor effects. Inhibition of cyclooxygenase-2 may lead to reductions in both prostagladinE2 and prostacyclin. Inhibition of ProstaglandinE2 may promote an acute relative reduction in daily urinary sodium excretion. The kidneys in patients with normal kidney function will tend to increase sodium excretion to compensate for the antinatriuretic effects of the Cyclooxygenase-2 selective inhibitor or Non steroidal anti inflammatory drug to maintain homeostasis of sodium balance. This phenomenon occurs in lack of a elevation in blood pressure or sustained rise in plasma volume. Suppression of the Cyclooxygenase -2?dependent formation of prostaglandinI2 by the coxibs might influence in patients to myocardial infarction or thrombotic stroke. Thus, reduction in prostaglandinI2 formation, lead to a expected elevation of blood pressure, accelerate atherogenesis, patients receiving coxibs to an exaggerated thrombotic response to the rupture of an atherosclerotic plaque.
Keywords
How to Cite This Article
Jossy P Jose,Shanmuga Sundaram Rajagopal and Sambath kumar Ramanathan. (2018); AN OVERVIEW ON NON STEROIDAL ANTI-INFLAMMATORY DRUG AS A TRIGGER OF CARDIOVASCULAR DISEASE., International Journal of Advanced Research (IJAR), 6 (02), 58-61, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/6408
Corresponding Author
Article Analytics
References
- Brooks PM, Day RO. Non-steroidal anti-inflammatory drugs: differences and similarities.N Engl J Med.?1991; 324:1716-25.
- Clive DM, Stoff JS. Renal syndromes associated with non steroidal anti-inflammatory N Engl J Med.?1984; 310:563-72.
- Silverstein FE, Faich G, Goldstein JL. Gastrointestinal toxicity with celecoxib vs non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. ?2000; 284:1247-55.
- Bombardier C, Laine L, Reicin A, Shapiro D . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.N Engl J Med 2000; 343:1520-1528
- Helin-Salmivaara,A.Virtanen,R.Vesalainen,etal., NSAID use and the risk hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur. Heart J.2006; 27:1657?1663.
- Amer M, Bead VR, Bathon J, Blumenthal RS, Edwards DN. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev.?2010; 18:204-12
- Rostom, P. Moayyedi, and R. Hunt. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastro protection: benefits versus risks. Alimentary Pharmacology& Therapeutics. 2009; 29:481?496.
- Farkouh ME and Greenberg BP, An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol.2009 ;103:1227-3
- Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors.2001; 286:954-9.
- 11 Kohli P, Steg PG, Cannon CP, smith SC Jr, Eagle KA, Ohman EM et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. AmJ Med.2014;127:53-60
- Mamdani M ,Juurlink DN , Lee DS, Rochon PA, Kopp A, Nagile G et al. Cyclooxygenase- 2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.2004; 36:1751-6
- Mukherjee D, Nissen SE, Topol EJ.Risk of cardiovascular events associated with selective COX-2 inhibitors. ?2001. 22-29; 286:954-9
- Bhala N, Emberson J, Merhi A, Abrmson S, Arber N, Baron JA et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. 2013; 382: 769?779
- Kearney PM, Baigent C,Godwin J, Halls H, Emberson JR ,Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.?2006 ;332:1302-8
- Garret A,FitzGerald M.D, Carlo Patrono M.D The coxibs, selective inhibitors ofcyclooxygenase-2.N Engl J Med 2001; 345:433-442
- FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov.?2003:2:879-90
- Zhang E. Ding L, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA2006; 29:1619?1632.
- Capone ML, Sciulli MG, Tacconelli S, Grana M,Ricciotti E, Renda G etal. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol.?2005; 45(8):1295-301
- Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. 2007 ;109:2285-92.
- White WB. Hypertension associated with therapies to treat arthritis and pain. Am Heart Assoc.2004; 44: 123?124.
- Janet E, Jennifer J, David T.A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993; 153:477? 484.
- Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994; 121: 289?300.
- White WB. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med.2000; 160:149 ?150.
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2000;283: 1967?1975.
- Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. 2004;19: 363:2022?2031.
- Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am JHypertens.2000; 13:1161?1167.
- Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB et al .Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther. 2002; 72:50?61.
- Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC.Controversies in COX-2 selective inhibition. J Rheumatol. 2002; 29:1501?1510.
- Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med.1999; 107:65S?70S.
- Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis GS. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000; 160:1465?1470.
Similar Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.





